Anthony P. Y. Liu,Sandeep K. Dhanda,Tong Lin,Edgar Sioson,Aksana Vasilyeva,Brian Gudenas,Ruth G. Tatevossian,Sujuan Jia,Geoffrey Neale,Daniel C. Bowers,Tim Hassall,Sonia Partap,John R. Crawford,Murali Chintagumpala,Eric Bouffet,Geoff McCowage,Alberto Broniscer,Ibrahim Qaddoumi,Greg Armstrong,Karen D. Wright,Santhosh A. Upadhyaya,Anna Vinitsky,Christopher L. Tinkle,John Lucas,Jason Chiang,Daniel J. Indelicato,Robert Sanders,Paul Klimo,Frederick A. Boop,Thomas E. Merchant,David W. Ellison,Paul A. Northcott,Brent A. Orr,Xin Zhou,Arzu Onar-Thomas,Amar Gajjar,Giles W. Robinson

Abstract:Methylation profiling has radically transformed our understanding of tumors previously called central nervous system primitive neuro-ectodermal tumors (CNS-PNET). While this marks a momentous step toward defining key differences, reclassification has thrown treatment into disarray. To shed light on response to therapy and guide clinical decision-making, we report outcomes and molecular features of children with CNS-PNETs from two multi-center risk-adapted studies (SJMB03 for patients ≥ 3 years; SJYC07 for patients < 3 years) complemented by a non-protocol institutional cohort. Seventy patients who had a histological diagnosis of CNS-PNET or CNS embryonal tumor from one of the new categories that has supplanted CNS-PNET were included. This cohort was molecularly characterized by DNA methylation profiling ( n = 70), whole-exome sequencing ( n = 53), RNA sequencing ( n = 20), and germline sequencing ( n = 28). Clinical characteristics were detailed, and treatment was divided into craniospinal irradiation (CSI)-containing (SJMB03 and SJMB03-like) and CSI-sparing therapy (SJYC07 and SJYC07-like). When the cohort was analyzed in its entirety, no differences were observed in the 5-year survival rates even when CSI-containing therapy was compared to CSI-sparing therapy. However, when analyzed by DNA methylation molecular grouping, significant survival differences were observed, and treatment particulars provided suggestions of therapeutic response. Patients with CNS neuroblastoma with FOXR2 activation (CNS-NB-FOXR2) had a 5-year event-free survival (EFS)/overall survival (OS) of 66.7% ± 19.2%/83.3% ± 15.2%, and CIC rearranged sarcoma (CNS-SARC-CIC) had a 5-year EFS/OS both of 57.1% ± 18.7% with most receiving regimens that contained radiation (focal or CSI) and multidrug chemotherapy. Patients with high-grade neuroepithelial tumor with BCOR alteration (HGNET-BCOR) had abysmal responses to upfront chemotherapy-only regimens (5-year EFS = 0%), but survival extended with salvage radiation after progression [5-year OS = 53.6% ± 20.1%]. Patients with embryonal tumor with multilayered rosettes (ETMR) or high-grade glioma/glioblastoma multiforme (HGG/GBM) did not respond favorably to any modality (5-year EFS/OS = 10.7 ± 5.8%/17.9 ± 7.2%, and 10% ± 9.0%/10% ± 9.0%, respectively). As an accompaniment, we have assembled this data onto an interactive website to allow users to probe and query the cases. By reporting on a carefully matched clinical and molecular cohort, we provide the needed insight for future clinical management.

The spectrum of morphological findings in pediatric central nervous system MN1-fusion-positive neuroepithelial tumors

Rare Oncogenic Fusions in Pediatric Central Nervous System Tumors: A Case Series and Literature Review

Clinical, pathologic, and genomic characteristics of two pediatric glioneuronal tumors with a CLIP2::MET fusion

Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion

Pediatric Mesenchymal Tumor With MN1::TAF3 Fusion

Lack of classical astroblastoma features in pediatric MN1::BEND2-fused brain tumors

Spectrum and Clinical Features of Gene Mutations in Chinese Pediatric Acute Lymphoblastic Leukemia

Identifying tumor type and cell type-specific gene expression alterations in pediatric central nervous system tumors

Tumeur neuroépithéliale avec fusion PATZ1 – à propos d’un cas et mise au point sur une entité mal définie

An integrative histopathological and epigenetic characterization of primary intracranial mesenchymal tumors, FET:CREB‐fused broadening the spectrum of tumor entities in comparison with their soft tissue counterparts

Pediatric Pan-Central Nervous System Tumor Methylome Analyses Reveal Immune-Related LncRNAs

Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials

Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population

Malignant tumors in children with neurofibromatosis Type 1

A comprehensive histomolecular characterization of meningioangiomatosis: Further evidence for a precursor neoplastic lesion

Paediatric diffuse leptomeningeal tumor with glial and neuronal differentiation harbouring chromosome 1p/19q co-deletion and H3.3 K27M mutation: unusual molecular profile and its therapeutic implications

CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomas

Aggressive Pediatric Primitive Round Cell Tumors with MN1::ZNF341 Fusion: A Mimic of Neuroblastoma

Malignant Transformation of a Dysembryoplastic Neuroepithelial Tumor (DNET) Characterized by Genome-Wide Methylation Analysis

Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas

Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas